Bifogade filer
Alligator receives approximately SEK 13.8 million through the exercise of warrants of series TO 6
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
The exercise period for warrants series TO 6 in Alligator Bioscience AB (publ) (“Alligator” or the “Company”) ended on 31 August 2023. A total of 275,027,774 warrants were exercised for the subscription of 34,378,471 new ordinary shares, corresponding to a utilization rate of approximately 68 percent.
Eight (8) warrants of series TO 6 entitled the holder to subscribe for one (1) new ordinary share in the Company at a subscription price of SEK 0.40 per share. A total of 275,027,774 warrants were exercised, corresponding to approximately 68 percent of all warrants of series TO 6, for the subscription of a total of 34,378,471 ordinary shares. Through the exercised warrants, Alligator receives approximately SEK 13.8 million before issue costs.
Increase in number of shares and share capital
Through the warrant exercise, the number of shares in Alligator increases by 34,378,471 ordinary shares, from a total of 624,525,669 to 658,904,140 shares, of which 657,954,290 are ordinary shares and 949,850 are series C shares. The share capital increases by SEK 2,200,222.144 to SEK 42,169,864.960. For existing shareholders who have not exercised any warrants, the dilution amounts to approximately 5.2 percent based on the number of shares in Alligator after the exercise of warrants. The total number of votes in the Company after the exercise of the warrants amounts to 658,049,275.
Delivery of subscribed shares
Subscribers of new shares through the exercise of warrants will receive interim shares (Sw. interimsaktier, IA) pending registration of the new shares with the Swedish Companies Registration Office (Sw. Bolagsverket). The conversion of interim shares into ordinary shares is estimated to take place around week 37 and the new ordinary shares will thereafter be admitted to trading on Nasdaq Stockholm.
Advisers
DNB Markets, a part of DNB Bank ASA, Sweden Branch and Redeye AB act as Joint Global Coordinators in connection with the Rights Issue. Setterwalls Advokatbyrå AB acts as legal adviser and Aktieinvest FK AB acts as the issuing agent in connection with the Rights Issue.